Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Levis

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Best Practice & Research. Clinical Haematology|December 7, 2010
Will newer tyrosine kinase inhibitors have an impact in AML?Mark J Levis
Clinical Advances in Hematology & Oncology : H&O|August 23, 2019
Midostaurin for patients with acute myeloid leukemia and FLT3 mutationsMark J Levis
Haematologica|November 27, 2025
The best laid schemesMark J Levis
British Journal of Haematology|August 5, 2021
Updates on targeted therapies for acute myeloid leukaemiaSabine Kayser, Mark J Levis
Current Oncology Reports|February 22, 2023
An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic LandscapeRebecca Bystrom, Mark J Levis
Leukemia & Lymphoma|May 2, 2013
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsSabine Kayser, Mark J Levis
International Journal of Hematologic Oncology|October 11, 2018
Are FLT3 inhibitors likely to improve <i>FLT3</i>-mutated acute myeloid leukemia in the foreseeable future?Sabine Kayser, Mark J Levis
British Journal of Haematology|December 2, 2017
Advances in targeted therapy for acute myeloid leukaemiaSabine Kayser, Mark J Levis
European Journal of Haematology|September 12, 2018
Clinical implications of molecular markers in acute myeloid leukemiaSabine Kayser, Mark J Levis
Haematologica|February 1, 2023
The clinical impact of the molecular landscape of acute myeloid leukemiaSabine Kayser, Mark J Levis
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Best Practice & Research. Clinical Haematology|December 7, 2010
Will newer tyrosine kinase inhibitors have an impact in AML?Mark J Levis
Clinical Advances in Hematology & Oncology : H&O|August 23, 2019
Midostaurin for patients with acute myeloid leukemia and FLT3 mutationsMark J Levis
Haematologica|November 27, 2025
The best laid schemesMark J Levis
British Journal of Haematology|August 5, 2021
Updates on targeted therapies for acute myeloid leukaemiaSabine Kayser, Mark J Levis
Current Oncology Reports|February 22, 2023
An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic LandscapeRebecca Bystrom, Mark J Levis
Leukemia & Lymphoma|May 2, 2013
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsSabine Kayser, Mark J Levis
International Journal of Hematologic Oncology|October 11, 2018
Are FLT3 inhibitors likely to improve <i>FLT3</i>-mutated acute myeloid leukemia in the foreseeable future?Sabine Kayser, Mark J Levis
British Journal of Haematology|December 2, 2017
Advances in targeted therapy for acute myeloid leukaemiaSabine Kayser, Mark J Levis
European Journal of Haematology|September 12, 2018
Clinical implications of molecular markers in acute myeloid leukemiaSabine Kayser, Mark J Levis
Haematologica|February 1, 2023
The clinical impact of the molecular landscape of acute myeloid leukemiaSabine Kayser, Mark J Levis
Pageof 14